Expression of IGSF9 in epithelial ovarian cancer and its effect on metastasis of ovarian cancer cells

doi:10.3760/cma.j.issn.1007-1245.2023.16.011

Abstract

Abstract:

Objective　To study the expression of immunoglobulin superfamily member 9 (IGSF9) in epithelial ovarian cancer (EOC), to analyze its relationship with prognosis and clinicopathological characteristics of EOC patients, and to explore the effect of IGSF9 on the metastatic ability of ovarian cancer cells. Methods　The expression of IGSF9 mRNA was analyzed by dynamic analysis website of gene expression profile data (GEPIA). The relationship between IGSF9 expression and the patients' survival time was analyzed by the Kaplan-Meier Plotter database. A total of 76 paraffin samples from the primary lesions of the EOC patients who were treated in Department of Gynecology, Tengzhou Central People's Hospital from June 2010 to June 2020 and 30 paraffin samples from the normal ovarian tissue removed due to other diseases during the same period were selected. The expressions of IGSF9 in the EOC patients' tissue and normal tissue were detected by the immunohistochemical staining; the correlation between IGSF9 expression and clinicopathological characteristics was analyzed. The SKOV3 ovarian cancer cell line interfered by IGSF9 was constructed by shRNA. Real-time fluorescent quantitative polymerase chain reaction (qRT-PCR) was used to identify the interference effect. The Transwell chamber method was used to detect the metastasis ability of SKOV3 cell line after IGSF9 interference. t test, analysis of variance, and χ² test were applied. Results　The GEPIA database showed that the expression level of IGSF9 in EOC was 21.8 times that in normal tissue. The 5-year overall survival and progression-free survival of the patients with high IGSF9 expression were poor. The high expression rates of IGSF9 in the EOC tissue and normal ovarian tissue were 69.7% and 16.7%, respectively. The expression of IGSF9 protein was correlated with FIGO stage, peritoneal metastasis, and serum carbohydrate antigen (CA-125) level in the EOC patients. Interference with IGSF9 expression resulted in decreased metastatic ability of ovarian cancer cells. Conclusions　The increased expression of IGSF9 in EOC is related to poor prognosis and poor clinicopathological characteristics of EOC patients. IGSF9 can promote the metastasis of ovarian cancer cells. IGSF9 may promote the progress of EOC, and has certain value for the diagnosis, treatment, and prognosis evaluation of EOC patients.

Key words:

Epithelial ovarian cancer, IGSF9, Prognosis, Clinicopathological features, Tumor metastasis

摘要：

目的　研究免疫球蛋白超家族成员9（IGSF9）在上皮性卵巢癌（epithelial ovarian cancer，EOC）中的表达，分析其与EOC患者预后及临床病理特征之间的关系，探究IGSF9对卵巢癌细胞转移能力的影响。方法　使用基因表达谱数据动态分析（GEPIA）网站综合分析IGSF9 mRNA表达情况，Kaplan-Meier Plotter数据库分析IGSF9表达与卵巢癌患者生存期之间的关系。选取2010年6月至2020年6月于滕州市中心人民医院妇科就诊的EOC患者原发病灶石蜡样本76例及同期因其他疾病切除的正常卵巢组织石蜡标本30例，免疫组织化学染色检测IGSF9在EOC患者组织和正常组织的表达并分析EOC患者中IGSF9表达与患者的临床病理特征之间的相关性。使用shRNA构建IGSF9干扰的SKOV3卵巢癌细胞株，通过实时荧光定量聚合酶链式反应（qRT-PCR）鉴定干扰效果，使用Transwell小室法检测干扰IGSF9后SKOV3细胞株转移能力。采用t检验、方差分析和χ²检验。结果　GEPIA数据库显示，IGSF9在EOC中的表达水平是正常组织的21.8倍；高表达IGSF9的患者5年整体生存期和无进展生存期均较差。免疫组化显示，IGSF9在EOC组织和正常卵巢组织的高表达率分别是69.7%和16.7%；IGSF9蛋白的表达与EOC患者的FIGO分期、腹腔转移、血清糖类抗原（CA）-125水平有相关性；干扰IGSF9后卵巢癌细胞转移能力减低。结论　IGSF9在EOC中表达升高，且与EOC患者预后不良及较差的临床病理特征有关；IGSF9能够促进卵巢癌细胞转移；IGSF9能促进EOC的进展；IGSF9对患者的诊治及预后判断有一定价值。

关键词:

上皮性卵巢癌, IGSF9, 预后, 临床病理特征, 肿瘤转移

Ding Baijuan, Zhang Liwei, Yang Hui, Cui Xiujuan, Li Nan.

Expression of IGSF9 in epithelial ovarian cancer and its effect on metastasis of ovarian cancer cells [J]. International Medicine and Health Guidance News, 2023, 29(16): 2268-2272.

丁佰娟张立伟杨慧崔秀娟李南.

IGSF9在上皮性卵巢癌中的表达及对卵巢癌细胞转移能力的影响 [J]. 国际医药卫生导报, 2023, 29(16): 2268-2272.

References

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI: 10.3322/caac.21590.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015 [J]. CA Cancer J Clin, 2016, 66(2):115-132. DOI: 10.3322/caac.21338.
[3] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3):209-249. DOI: 10.3322/caac.21660.
[4] Baci D, Bosi A, Gallazzi M, et al. The ovarian cancer tumor immune microenvironment (TIME) as target for therapy: a focus on innate immunity cells as therapeutic effectors [J]. Int J Mol Sci, 2020, 21(9): 3125. DOI: 10.3390/ijms21093125.
[5] Jayson GC, Kohn EC, Kitchener HC, et al. Ovarian cancer [J]. Lancet, 2014, 384(9951): 1376-1388. DOI: 10.1016/S0140-6736(13)62146-7.
[6] Doudney K, Murdoch JN, Braybrook C, et al. Cloning and characterization of IGSF9 in mouse and human: a new member of the immunoglobulin superfamily expressed in the developing nervous system [J]. Genomics. 2002 May;79(5):663-70. DOI: 10.1006/geno.2002.6757.
[7] Hansen M, Walmod PS. IGSF9 family proteins [J]. Neurochem Res, 2013, 38(6):1236-1251. DOI: 10.1007/s11064-013-0999-y.
[8] Shi SH, Cox DN, Wang D, et al. Control of dendrite arborization by an Ig family member, dendrite arborization and synapse maturation 1 (Dasm1) [J]. Proc Natl Acad Sci U S A, 2004, 101(36):13341-13345. DOI: 10.1073/pnas.0405370101.
[9] Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas [J]. Cancer Biol Ther, 2005, 4(9):1018-1029. DOI: 10.4161/cbt.4.9.2165.
[10] Kim JH, Kim HN, Lee KT, et al. Gene expression profiles in gallbladder cancer: the close genetic similarity seen for early and advanced gallbladder cancers may explain the poor prognosis [J]. Tumour Biol, 2008, 29(1): 41-49. DOI: 10.1159/000132570.
[11] 闫小妮,田国祥,潘振宇,等. 如何挖掘GEPIA数据库中研究数据并生成分析结果表达图[J]. 中国循证心血管医学杂志,2019,11(5):521-525. DOI:10.3969/j.issn.1674-4055. 2019.05.03.
[12] Morand S, Devanaboyina M, Staats H, et al. Ovarian cancer immunotherapy and personalized medicine [J]. Int J Mol Sci, 2021, 22(12): 6532. DOI: 10.3390/ijms22126532.
[13] Konstantinopoulos PA, Norquist B, Lacchetti C, et al. Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline [J]. J Clin Oncol, 2020, 38(11):1222-1245. DOI: 10.1200/JCO.19.02960.
[14] McMullen M, Karakasis K, Madariaga A, et al. Overcoming platinum and PARP-inhibitor resistance in ovarian cancer [J]. Cancers (Basel), 2020, 12(6):1607. DOI: 10.3390/cancers12061607.
[15] Harjunpää H, Llort Asens M, Guenther C, et al. Cell adhesion molecules and their roles and regulation in the immune and tumor microenvironment [J]. Front Immunol, 2019, 10:1078. DOI: 10.3389/fimmu.2019. 01078.
[16] da Rosa Franchi Santos LF, Costa NT, Maes M, et al. Influence of treatments on cell adhesion molecules in patients with systemic lupus erythematosus and rheumatoid arthritis: a review [J]. Inflammopharmacology, 2020, 28(2):363-384. DOI: 10.1007/s10787-019-00674-6.
[17] Hintermann E, Christen U. The many roles of cell adhesion molecules in hepatic fibrosis [J]. Cells, 2019, 8(12):1503. DOI: 10.3390/cells8121503.
[18] Matthäus C, Langhorst H, Schütz L, et al. Cell-cell communication mediated by the CAR subgroup of immunoglobulin cell adhesion molecules in health and disease [J]. Mol Cell Neurosci, 2017, 81:32-40. DOI: 10.1016/j.mcn.2016.11.009.
[19] Ferraro TN, Golden GT, Smith GG, et al. Fine mapping of a seizure susceptibility locus on mouse chromosome 1: nomination of Kcnj10 as a causative gene [J]. Mamm Genome, 2004, 15(4):239-251. DOI: 10.1007/s00335- 003-2270-3.
[20] Shi Z, Li C, Tarwater L, et al. RNA-seq reveals the overexpression of IGSF9 in endometrial cancer [J]. J Oncol, 2018:2439527. DOI: 10.1155/2018/2439527.